Dilara Bulut Gökten, Mehmet Engin Tezcan, Burcu Yağız, Abdulsamet Erden, Gezmiş Kimyon, Nazife Şule Yaşar Bilge, Levent Kılıç, Belkıs Nihan Coşkun, Emine Duygu Ersözlü, Orhan Küçükşahin, Süleyman Serdar Koca, Emel Gönüllü, Muhammet Çınar, Servet Akar, Hakan Emmungil, Timuçin Kaşifoğlu, Cemal Bes, Aşkın Ateş, Yavuz Pehlivan, Sedat Kiraz, Ali İhsan Ertenli, Hüseyin Ediz Dalkılıç, Umut Kalyoncu, Rıdvan Mercan
{"title":"Real-World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease","authors":"Dilara Bulut Gökten, Mehmet Engin Tezcan, Burcu Yağız, Abdulsamet Erden, Gezmiş Kimyon, Nazife Şule Yaşar Bilge, Levent Kılıç, Belkıs Nihan Coşkun, Emine Duygu Ersözlü, Orhan Küçükşahin, Süleyman Serdar Koca, Emel Gönüllü, Muhammet Çınar, Servet Akar, Hakan Emmungil, Timuçin Kaşifoğlu, Cemal Bes, Aşkın Ateş, Yavuz Pehlivan, Sedat Kiraz, Ali İhsan Ertenli, Hüseyin Ediz Dalkılıç, Umut Kalyoncu, Rıdvan Mercan","doi":"10.1111/1756-185X.70274","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>The objective was to evaluate biologic disease-modifying antirheumatic drugs (DMARDs) and their side effects that hindered the continuation of treatment in a patient population diagnosed with spondyloarthritis (SpA) with a glomerular filtration rate (GFR) ≤ 60 mL/min, and to compare these side effects between patients with chronic kidney disease (CKD) and those without.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This multicenter, observational cohort study utilized data from the TReasure database, which records SpA patients in a web-based system across Türkiye. A total of 6052 patients being included. SpA patients were categorized into two main groups: non-CKD patients and CKD patients. The clinical characteristics, disease activity, treatment options, drug retention rates, reasons for drug discontinuation, and types of adverse effects were compared between the groups.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Biologics prescription pattern varied between CKD and non-CKD patients. Etanercept was prescribed more frequently (53.1%) in CKD patients. Regarding the number of side effects and drug discontinuations in CKD patients, no statistically significant differences were found between the non-CKD and CKD groups for any of the bDMARDs (adalimumab, etanercept, golimumab, infliximab, ustekinumab, secukinumab, and certolizumab). No statistically significant differences were observed in the duration of drug retention based on CKD status for bDMARDs.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study offers preliminary evidence supporting the effective and safe use of bDMARDs in patients with SpA and CKD.</p>\n </section>\n </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 5","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70274","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1756-185X.70274","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim
The objective was to evaluate biologic disease-modifying antirheumatic drugs (DMARDs) and their side effects that hindered the continuation of treatment in a patient population diagnosed with spondyloarthritis (SpA) with a glomerular filtration rate (GFR) ≤ 60 mL/min, and to compare these side effects between patients with chronic kidney disease (CKD) and those without.
Methods
This multicenter, observational cohort study utilized data from the TReasure database, which records SpA patients in a web-based system across Türkiye. A total of 6052 patients being included. SpA patients were categorized into two main groups: non-CKD patients and CKD patients. The clinical characteristics, disease activity, treatment options, drug retention rates, reasons for drug discontinuation, and types of adverse effects were compared between the groups.
Results
Biologics prescription pattern varied between CKD and non-CKD patients. Etanercept was prescribed more frequently (53.1%) in CKD patients. Regarding the number of side effects and drug discontinuations in CKD patients, no statistically significant differences were found between the non-CKD and CKD groups for any of the bDMARDs (adalimumab, etanercept, golimumab, infliximab, ustekinumab, secukinumab, and certolizumab). No statistically significant differences were observed in the duration of drug retention based on CKD status for bDMARDs.
Conclusion
This study offers preliminary evidence supporting the effective and safe use of bDMARDs in patients with SpA and CKD.
期刊介绍：
The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
